[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-426516-105":59,"doc-detail-426516-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","methods-to-crosswalk-between-cognitive-test-scores-using-data-from-the-alzheimers-disease-neuroimaging-cohort","METHODS TO CROSSWALK BETWEEN COGNITIVE TEST SCORES USING DATA FROM THE ALZHEIMER’S DISEASE NEUROIMAGING COHORT","","Studies use multiple instruments to measure dementia-related outcomes, making comparisons of intervention or exposure effects challenging across clinical trials. Trials of anti-amyloid drugs report CDR-SB as a primary outcome, while earlier studies used MMSE or the Alzheimer’s Disease Assessment Scale–Cognitive Subscale. To enable integration, psychometric harmonization is limited by unverifiable assumptions and inability with summary statistics. Two flexible crosswalk methods estimate treatment effects across cognitive measures using ADNI examples, including CDR-SB, MoCA, and MMSE, and demonstrate settings where crosswalking is inappropriate (p-tau with global cognition).",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/methods-to-crosswalk-between-cognitive-test-scores-using-data-from-the-alzheimers-disease-neuroimaging-cohort/426516/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/methods-to-crosswalk-between-cognitive-test-scores-using-data-from-the-alzheimers-disease-neuroimaging-cohort/426516.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why is comparing dementia-related trial outcomes across instruments difficult?","Question",{"text":112,"@type":113},"Different studies use different measurement instruments for dementia-related outcomes, so intervention or exposure effects are reported on non-comparable scales.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What do the two crosswalk methods enable?",{"text":117,"@type":113},"They estimate treatment effects on cognitive outcomes using one measure to obtain estimates using another measure, using flexible approaches that do not require strong distributional assumptions.",{"name":119,"@type":110,"acceptedAnswer":120},"Which cognitive measures are used to illustrate the crosswalking methods?",{"text":121,"@type":113},"The methods are illustrated with global cognitive change measures including CDR-SB, MoCA, and MMSE, drawn from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).",{"name":123,"@type":110,"acceptedAnswer":124},"When is crosswalking not appropriate according to the document?",{"text":125,"@type":113},"Crosswalking is not appropriate in a setting illustrated with plasma phosphorylated tau (p-tau) concentration together with global cognitive measures.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},426516,1790763324,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":81},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","542 Innovation in Aging, 2025, Vol. 9, No. S2  \nAbstract citation ID: igaf122.1855  \nMETHODS TO CROSSWALK BETWEEN COGNITIVE  \nTEST SCORES USING DATA FROM THE ALZHEIMER’S  \nDISEASE NEUROIMAGING COHORT  \nSarah Ackley1, Jingxuan Wang2, Ruijia Chen3, Tanisha Hill-Jarrett4, L Paloma Rojas-Saunero5,  \nAndrew Stokes6, Sachin Shah7, and M. Maria Glymour6, 1. Brown University, Providence, Rhode Island, United States, 2.  \nUniversity of California, San Francisco, San Francisco, California, United States, 3. Boston University School of Public Health, Boston, Massachusetts, United States, 4. University of California Memory and Aging Center, San Francisco, California, United States, 5. University of California, Los Angeles, Los Angeles, California, United States, 6. Boston University, Boston, Massachusetts, United States, 7. Massachusetts General Hospital, Boston, Massachusetts, United States  \nStudies use multiple instruments to measure dementia-related outcomes, making comparisons of intervention or exposure effects challenging. For example, trials of anti-amyloid drugs like TRAILBLAZER-AD 2 (donanemab), CLARITY-AD (lecanemab), and GRADUATE I & II (gantenerumab) report changes in the clinical dementia rating sum of boxes (CDR-SB) as the primary outcome, while earlier trials used measures such as the Mini-Mental State Exam (MMSE) ortheAlzheimer’s DiseaseAssessment Scale-Cognitive Subscale. Comparing or meta-analyzing findings requires integrating effect estimates from different outcome measures. Psychometric methods can harmonize these measures but rely on unverifiable assumptions and do not work with summary statistics. To address this gap, we developed two methods to crosswalk estimated treatment effects on cognitive outcomes that are flexible, broadly applicable, and do not rely on strong distributional assumptions. We present two methods to crosswalk effect estimates using one measure to estimates using another measure, illustrated with global cognitive measures from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Specifically, we develop crosswalks for the following measures and associated change scores over time: the clinical dementia rating scale sum of box (CDR-SB), Montreal cognitive assessment (MoCA), and mini-mental state exam (MMSE) scores. Finally, a setting in which crosswalking is not appropriate is illustrated with plasma phosphorylated tau (p-tau) concentration and global cognitive measures. Given the inconsistent collection and reporting of dementia and cognitive outcomes across studies, these crosswalking methods offer a valuable approach to harmonizing and comparing results reported on different scales.","cbCaitjYldzdPTGS","https://ap.wps.com/l/cbCaitjYldzdPTGS","pdf",47685,"English","# Background\n## Measurement challenges and need for harmonization\n# Proposed methods\n## Crosswalking treatment effects across cognitive scales\n# Measures and change scores\n## CDR-SB, MoCA, MMSE over time\n# When crosswalking is not appropriate\n## Example using p-tau and global cognition","[{\"question\":\"Why is comparing dementia-related trial outcomes across instruments difficult?\",\"answer\":\"Different studies use different measurement instruments for dementia-related outcomes, so intervention or exposure effects are reported on non-comparable scales.\"},{\"question\":\"What do the two crosswalk methods enable?\",\"answer\":\"They estimate treatment effects on cognitive outcomes using one measure to obtain estimates using another measure, using flexible approaches that do not require strong distributional assumptions.\"},{\"question\":\"Which cognitive measures are used to illustrate the crosswalking methods?\",\"answer\":\"The methods are illustrated with global cognitive change measures including CDR-SB, MoCA, and MMSE, drawn from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).\"},{\"question\":\"When is crosswalking not appropriate according to the document?\",\"answer\":\"Crosswalking is not appropriate in a setting illustrated with plasma phosphorylated tau (p-tau) concentration together with global cognitive measures.\"}]","METHODS TO CROSSWALK BETWEEN COGNITIVE TEST SCORES USING DATA FROM THE ALZHEIMER’S DISEASE NEUROIMAGING COHORT | PDF",1790640805]